StockNews.com upgraded shares of Surmodics (NASDAQ:SRDX – Free Report) from a buy rating to a strong-buy rating in a research report sent to investors on Tuesday.
Separately, Needham & Company LLC reissued a buy rating and set a $47.00 target price on shares of Surmodics in a research report on Wednesday, April 10th.
View Our Latest Research Report on SRDX
Surmodics Stock Performance
Institutional Investors Weigh In On Surmodics
Several hedge funds and other institutional investors have recently made changes to their positions in SRDX. Legal & General Group Plc grew its position in Surmodics by 0.9% in the 2nd quarter. Legal & General Group Plc now owns 34,615 shares of the company’s stock worth $1,289,000 after purchasing an additional 302 shares in the last quarter. Yousif Capital Management LLC grew its position in Surmodics by 2.4% in the 1st quarter. Yousif Capital Management LLC now owns 12,777 shares of the company’s stock worth $579,000 after purchasing an additional 305 shares in the last quarter. Rhumbline Advisers grew its position in Surmodics by 0.8% in the 2nd quarter. Rhumbline Advisers now owns 37,138 shares of the company’s stock worth $1,383,000 after purchasing an additional 312 shares in the last quarter. Franklin Resources Inc. grew its position in Surmodics by 4.6% in the 4th quarter. Franklin Resources Inc. now owns 7,174 shares of the company’s stock worth $261,000 after purchasing an additional 317 shares in the last quarter. Finally, Gamco Investors INC. ET AL grew its position in Surmodics by 0.5% in the 2nd quarter. Gamco Investors INC. ET AL now owns 76,900 shares of the company’s stock worth $2,408,000 after purchasing an additional 400 shares in the last quarter. 96.63% of the stock is owned by institutional investors.
Surmodics Company Profile
Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).
See Also
- Five stocks we like better than Surmodics
- Golden Cross Stocks: Pattern, Examples and Charts
- Comprehensive PepsiCo Stock Analysis
- Best Stocks Under $5.00
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- How to Use the MarketBeat Dividend Calculator
- 3 Steel Stocks Could Soar on New China Tariffs
Receive News & Ratings for Surmodics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surmodics and related companies with MarketBeat.com's FREE daily email newsletter.